Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 12:00 ET | Source: Rivus Pharmaceuticals, Inc.

Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek®

First data from Rivus’ preclinical CMA pipeline showing potential as monotherapy and in combination with GLP-1s
November 04, 2025 12:00 ET | Source: Kailera Therapeutics, Inc.; Hengrui Pharma

Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

Hengrui Pharma & Kailera Therapeutics Present Additional Data from Phase 3 Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 at Obesity Week
October 21, 2025 07:00 ET | Source: Kailera Therapeutics, Inc.

Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025

Hengrui Pharma and Kailera today announced an oral presentation of HRS9531 Phase 3 data at ObesityWeek® 2025, the annual meeting of the Obesity Society.
October 07, 2025 09:00 ET | Source: Neurogastrx

Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®

Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®
December 14, 2016 18:00 ET | Source: UT MIST

Minimally Invasive Surgeons of Texas Members Speak at ObesityWeek

HOUSTON, TX--(Marketwired - December 14, 2016) - Presenting on topics ranging from intragastric balloons to sleeve gastrectomy, Houston-based doctors and other professionals from Minimally Invasive...